Immunoglobulin market size
According to the
report, Immunoglobulin
market size is projected reach USD 18,378.0 Million by
2026. Global Immunoglobulin market was USD 10,750.0 million in 2018 and is
anticipated to exhibit a CAGR of 7.0% during the forecast period set between
2019 to 2026. R
The increasing diagnosis rates owing to escalating awareness
regarding the treatment of immunoglobulins will have a tremendous effect on the
market during the forecast period.
The emergence of COVID-19 has brought the
world to a standstill. We understand that this health crisis has brought an
unprecedented impact on businesses across industries. However, this too shall
pass. Rising support from governments and several companies can help in the fight
against this highly contagious disease. There are some industries that are
struggling and some are thriving. Overall, almost every sector is anticipated
to be impacted by the pandemic.
Request
a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoglobulins-market-100571
Introduction
of Advanced Therapeutic to Augment Growth
The launch of novel advanced drugs such as
CUVITRU and BIVIGAM by Shire (Takeda Pharmaceutical Company Limited) and ADMA
Biologics Inc., respectively will impel manufactures to innovative drugs and
give competition to the rival companies, which, in turn, will spur
opportunities for the market. The increasing adoption of immunoglobulin therapy
as the first line of treatment for the primary immunodeficiency and other rare
immunological and neurological diseases will be a critical factor in promoting
the growth of the market.
The growing focus on the diagnosis of immune
disorders will foster the healthy growth of the market. The increasing
prevalence of numerous viruses and diseases has led to pre-diagnosis, which, in
turn, will augur well for the market. The growing efficiency of immunoglobulin
as an effective treatment option for several diseases such as primary
immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP)
will positively enable speedy expansion of the market in the foreseeable
future.
The market in North America generated a
revenue of US$ 6,291.5 Mn in 2017 and is and is predicted to remain dominant
during the forecast period. The growth in the region is attributed to the
acceptance of immunoglobulin as a first line of treatment for many critical
immune disorders.
Click here to get the short-term and long-term
impacts of COVID-19 on this Market:
https://www.fortunebusinessinsights.com/industry-reports/immunoglobulins-market-100571
Rising Patient Population to Aid Expansion in North America
The
increasing number of patients and the growing demand for novel therapies will
further aid the growth of the market in the region. Asia Pacific is predicted to hold the largest
share in the market owing to the demand for intravenous (IV) in the developing
nations. The increasing healthcare expenditure and rising investment for
advanced immunoglobulins will further enable growth in the region. The Middle
and Africa is likely to expand in the forthcoming years owing to the developing
healthcare infrastructure in the region.
Quick
Buy - Immunoglobulin Market Research
Report: https://www.fortunebusinessinsights.com/checkout-page/100571
FDA announced the approval of
prior approval supplement (PAS) for ADMA Biologics.
Kedrion S.p.A and Kamada
announced the launch of KEDRAB, an immunoglobulin aimed at the treatment of
rabies
·
Shire (Takeda
Pharmaceutical Company Limited)
·
CSL Behring
·
Grifols, S.A.
·
Kedrion S.p.A
·
Octapharma
·
Bio Products
Laboratory Ltd.
·
Biotest AG
·
China Biologic
Products Holdings, Inc.
·
LFB SA
·
Shanghai RAAS Blood
Products Co., Ltd.
Have
Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immunoglobulins-market-100571
Global Immunoglobulin Market Segmentations:
By Route of Administration
·
Intravenous
(IV
·
Subcutaneous (SC))
By Indication
·
Primary
Immunodeficiency
·
Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP)
·
Guillain-Barre
Syndrome (GBS)
·
Immune
Thrombocytopenic Purpura (ITP)
·
Multifocal
Motor Neuropathy (MMN))
By Form:
·
Liqui
·
Lyophilized
By End User
·
Hospitals
·
Clinics
·
Homecare
By Geography
•
North
America (U.S. and Canada)
•
Europe
(U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
•
Asia
Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia
Pacific)
•
Latin
America (Brazil, Mexico, and Rest of Latin America)
•
Middle
East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Get
your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/immunoglobulins-market-100571
Have a Look at Related Reports:
Kidney Stone Management Market Size,
Share & COVID-19 Impact Analysis, By Type (Lithotripsy, Ureteroscopy, and
Percutaneous Nephrolithonomy (PCNL) By End User (Hospitals, Specialty Clinics,
and Ambulatory Surgical Centers), and Regional Forecast, 2020-2027
Dental Materials Market Size, Share &
COVID-19 Impact Analysis, By Type (Metallic Biomaterials, Ceramic Biomaterials,
Polymers, Natural Biomaterials, and Others), By Application (Implant,
Prosthetics, and Orthodontics), By End User (Dental Product Manufacturers,
Dental Laboratories, and Others), and Regional Forecast, 2020-2027
Intensive Care Unit (ICU) Equipment Market Size,
Share and Covid-19 Impact Analysis, By Product (Beds, Ventilators, Pulse
Oximeters, Dialysis Equipment, and Others), By Patient (Adult and Pediatric),
By Application (Neurology, Cardiology, Respiratory, Renal, Oncology, Trauma,
and Others), By End-User (Hospitals, Specialty Clinics, and Others) and
Regional Forecast, 2020-2027
Bone Graft Substitutes Market Size,
Share & COVID-19 Impact Analysis, By Type (Autograft, Allograft,
Demineralized Bone Matrix (DBM), Synthetic, and Xenograft), By Application
(Spinal Fusion, Joint Reconstruction, Foot & Ankle, and Others), By End
User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027
Cystic Fibrosis Market Size, Share & Covid-19
Impact Analysis, By Drug Class (Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and
Others), By Route of Administration (Oral, and Parenteral), By Distribution
Channel (Retail Pharmacies & Drug Stores, Online Pharmacies, and Hospital
Pharmacies), and Regional Forecast, 2020-2027
About
Us:
Fortune Business Insights™ offers expert corporate
analysis and accurate data, helping organizations of all sizes make timely
decisions. We tailor innovative solutions for our clients, assisting them to
address challenges distinct to their businesses. Our goal is to empower our
clients with holistic market intelligence, giving a granular overview of the
market they are operating in.
Our reports contain a unique mix of tangible insights and
qualitative analysis to help companies achieve sustainable growth. Our team of
experienced analysts and consultants use industry-leading research tools and
techniques to compile comprehensive market studies, interspersed with relevant
data.
At Fortune Business Insights™ we aim at highlighting the
most lucrative growth opportunities for our clients. We, therefore, offer
recommendations, making it easier for them to navigate through technological
and market-related changes. Our consulting services are designed to help
organizations identify hidden opportunities and understand prevailing
competitive challenges.
Contact Us:
Fortune Business
Insights™ Pvt. Ltd.
308, Supreme
Headquarters,
Survey No. 36,
Baner,
Pune-Bangalore
Highway,
Pune - 411045,
Maharashtra, India.
Phone:
US :+1 424 253
0390
UK : +44 2071
939123
APAC : +91 744
740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment